A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer
Details
Publication Year 2022-03,Volume 18,Issue #10,Page 1185-1198
Journal Title
Future Oncology
Publication Type
Protocol
Abstract
Cabozantinib inhibits multiple receptor tyrosine kinases, including the TAM kinase family, and may enhance response to immune checkpoint inhibitors. One cohort of the ongoing phase Ib COSMIC-021 study (NCT03170960) evaluating cabozantinib plus the PD-L1 inhibitor atezolizumab in men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue on/after enzalutamide and/or abiraterone treatment for metastatic disease has shown promising efficacy. Here, we describe the rationale and design of a phase III trial of cabozantinib plus atezolizumab versus a second novel hormone therapy (NHT) in patients who have previously received an NHT for mCRPC, metastatic castration-sensitive PC or nonmetastatic CRPC and have measurable visceral disease and/or extrapelvic adenopathy - a population with a significant unmet need for treatment options. Trial Registration Clinical Trial Registration: NCT04446117 (ClinicalTrials.gov) Registered on 24 June 2020.
Keywords
Adenocarcinoma/*drug therapy/pathology; Androstenes/therapeutic use; Anilides/*therapeutic use; Antibodies, Monoclonal, Humanized/*therapeutic use; Antineoplastic Agents, Hormonal/*therapeutic use; Benzamides/therapeutic use; Humans; Immune Checkpoint Inhibitors/*therapeutic use; Male; Neoplasm Metastasis; Nitriles/therapeutic use; Phenylthiohydantoin/therapeutic use; Prostatic Neoplasms, Castration-Resistant/*drug therapy/pathology; Pyridines/*therapeutic use; Receptor Protein-Tyrosine Kinases/antagonists & inhibitors; TAM kinase inhibitor; atezolizumab; cabozantinib; immune checkpoint inhibitor; metastatic castration-resistant prostate cancer; novel hormone therapy; phase III; receptor tyrosine kinase inhibitor; trial in progress
Department(s)
Medical Oncology
PubMed ID
35034502
Open Access at Publisher's Site
https://doi.org/10.2217/fon-2021-1096
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-25 04:53:30
Last Modified: 2024-09-25 05:00:19

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙